Stilgenbauer, S. Et Al. 2021. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. British Journal of Haematology , vol.193, no.2 , 325-338.

Stilgenbauer, S., Bosch, F., İLHAN, ., Kisro, J., Mahé, B., Mikuskova, E., ... Osmanov, D.(2021). Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. British Journal of Haematology , vol.193, no.2, 325-338.

Stilgenbauer, Stephan Et Al. "Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study," British Journal of Haematology , vol.193, no.2, 325-338, 2021

Stilgenbauer, Stephan Et Al. "Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study." British Journal of Haematology , vol.193, no.2, pp.325-338, 2021

Stilgenbauer, S. Et Al. (2021) . "Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study." British Journal of Haematology , vol.193, no.2, pp.325-338.

@article{article, author={Stephan Stilgenbauer Et Al. }, title={Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study}, journal={British Journal of Haematology}, year=2021, pages={325-338} }